The Lead Podcast presented by Heart Rhythm Society The Lead Podcast presented by Heart Rhythm Society

Bruce A. Koplan, MD, MPH, FHRS, Brigham Women's Hospital is joined by Matthew R. Reynolds, MD, MS, FHRS, Lahey Hospital & Medical Center, and Esseim Sharma, MD, University Hospitals Cleveland to discuss integrating patient-specific cardiac implantable electronic device (CIED)-detected atrial fibrillation (AF) burden with measures of health care cost and utilization allows for an accurate assessment of the AF-related impact on health care use. 
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/full/10.1016/j.jacep.2023.12.011
Host Disclosure(s):
B. Koplan: Speaking/Consulting Honoraria: GE Healthcare
Contributor Disclosure(s):
M. Reynolds: Speaking, Teaching, and Consulting: Medtronic, Edwards Lifesciences, Philips, iRhythm Technologies, Membership on Advisory Committees: Affera, Inc.
E. Sharma: Nothing to disclose.
This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365     https://www.heartrhythm365.org/URL/TheLeadEpisode61

Deepthy Varghese, MSN, ACNP, FNP, Northside Hospital, is joined by Shephal K Doshi, MD Pacific Heart Institute, and Devi G. Nair, MD, FHRS, St. Bernards Medical Center & Arrhythmia Research Group to discuss how the retrospective cohort study examined the safety and efficacy of combining left atrial appendage occlusion (LAAO) with other cardiac procedures compared to isolated LAAO. Based on data from the National Inpatient Sample database, the analysis found similar rates of major adverse cardiovascular events (MACEs) and length of stay (LOS) between the two groups. However, patients undergoing concomitant procedures had higher costs and certain complications were more frequent, such as heart block with atrial fibrillation/atrial flutter ablation and stroke with transcatheter aortic valve replacement. 
 
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/10.1016/j.jcin.2023.10.017
 
Host Disclosure(s):
D. Varghese: Nothing to disclose.
 
Contributor Disclosure(s):
S. Doshi: Research: Biosense Webster, Inc., Abbott Medical, Boston Scientific, Galvanize Therapeutics
D. Nair: Honoraria, Speaking, and Consulting: Medtronic, Biosense Webster, Inc., Boston Scientific, Abbott Medical
This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode60

Jason T. Jacobson, MD, FHRS, Westchester Medical Center-New York Medical College, is joined by William H. Sauer, MD, FHRS, Brigham and Women's Hospital, and Christian Thomas Ruff, MD, Brigham and Women's Hospital to discuss a meta-analysis of the 2 recent randomized controlled trials of oral anticoagulation vs aspirin and placebo for atrial high rate episodes detected by cardiac implanted electronic devices. The trials included are NOAH-AFNET6 and ARTESIA, which reported discordant results. When analyzed together, this study shows that anticoagulation does decrease embolic risk in this patient population.
 
https://www.hrsonline.org/education/TheLead
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
 
Host Disclosure(s):
J. Jacobson: Honoraria/Speaking/Consulting: American College of Cardiology, Zoll Medical Corporation, Research: Abbott, Phillips, Stock, Privately Held: Atlas 5D
 
Contributor Disclosure(s):
C. Ruff: Honoraria/Speaking/Consulting: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals, Research: Daiichi, MedImmune
W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic 

Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by Fred M. Kusumoto, MD, FHRS, Mayo Clinic Jacksonville, and Julia H. Indik, MD, PhD, FHRS, University of Arizona Medical Center (CVD) to discuss how Atrial fibrillation (AF) is a chronic progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia. 
 
https://www.hrsonline.org/education/TheLead

https://doi.org/10.1093/eurheartj/ehad572
 
Host Disclosure(s):

J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association
 
Contributor Disclosure(s):

J. Indik: Honoraria, Other Financial Relationships: American College of Cardiology, Honoraria/Speaking/Consulting: Heart Rhythm Society

F. Kusumoto: Nothing to disclose
 
This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode58

Michael S. Lloyd, MD, FHRS, Emory University, is joined by guest Christopher R. Ellis, MD, FHRS, Vanderbilt Heart, and Stacy B. Westerman, MD, MPH, Emory University, to discuss Esophageal deviation devices for AF Ablation.
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/10.1016/j.jacep.2023.09.004#:~:text=The%20EASY%20AF%20trial%20(EsophAguS,esophageal%20lesions%20attributable%20to%20RFA
Host Disclosure(s):
M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Baylis Medical Company, Boston Scientific
Contributor Disclosure(s):
C. Ellis: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Medtronic, Boehringer Ingelheim
S. Westerman: Honoraria/Speaking/Consulting: Boston Scientific 
This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365     https://www.heartrhythm365.org/URL/TheLeadEpisode57

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by guest Amin Al-Ahmad, MD, FHRS, CCDS, Texas Cardiac Arrhythmia Institute and Jorge Romero, Jr., MD, FHRS, Brigham and Women's Hospital to discuss how Pulsed-field ablation (PFA) is a novel nonthermal ablation technology with high procedural safety and efficiency for pulmonary vein isolation (PVI). Premarket data showed high PVI durability during mandatory remapping studies. Data on lesion durability in real-world patients with clinically indicated redo procedures are scarce. In this episode of The Lead, we discuss why and how this study sought to report PVI durability rates in patients undergoing a clinically indicated redo procedure after an index PVI using PFA.
https://www.hrsonline.org/education/TheLead
https://www.jacc.org/doi/10.1016/j.jacep.2023.11.026
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic
Contributor Disclosure(s):
A. Al-Ahmad: Honoraria/Speaking/Consulting: Abbott, Biosense Webster, Inc., Boston Scientific, Haemonetics, Mediasphere Medical, Medtronic, Philips, Stocks, Privately Held: Soundcath
J. Romero: Honoraria/Speaking/Consulting: Sanofi, Boston Scientific, AtriCure, Inc.